Insulin resistance status is an important determinant of PAI-1 levels in HIV-infected patients, independently of the lipid profile [6]

Journal of Thrombosis and Haemostasis

Volumn 2, Issue 3, 2004, Pages 532-534

  De Larrañaga, Gabriela ^a,d   Galich, A ^b,d   Puga, L ^c,d   Alonso, B ^a,d   Benetucci, J ^c,d  

^a HOSPITAL F J MUÑIZ   (Argentina)

^b HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^c Retrovirus Laboratory of FUNDAI   (Argentina)

^d Argentinian Grp of AIDS Researchers   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; APOLIPOPROTEIN B; GLUCOSE; INSULIN; LIPID; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PADGEM PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR; PROTEINASE INHIBITOR; TRIACYLGLYCEROL; URIC ACID; PLASMINOGEN ACTIVATOR INHIBITOR 1;

CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; GLUCOSE BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HOMEOSTASIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; LETTER; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PATIENT SELECTION; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; THROMBOCYTE ACTIVATION; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL; BLOOD; PHYSIOLOGY; REFERENCE VALUE;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HUMANS; INSULIN RESISTANCE; LIPIDS; PLASMINOGEN ACTIVATOR INHIBITOR 1; REFERENCE VALUES;

EID: 6944250346     PISSN: 15387933     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2004.00602.x     Document Type: Letter

References (8)

1. Meigs JB, Mittleman MA, Nathan DM, Tofler GH, Singer DE, Murphy-Sheehy PM, Lipinska I, D'Agostino RB, Wilson PWF. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham offspring study. JAMA 2000; 283: 221-8.
2. Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes 1997; 46: 860-7.
3. Festa A, D'Agostino R, Tracy RP, Haffner SM. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2002; 51: 1131-7.
4. Safrin S, Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection. AIDS 1999; 13: 2493-505.
5. Grinspoon S. Insulin resistance in the HIV-lipodystrophy syndrome. Trends Endocrinol Metab 2001; 9: 413-9.
6. Holme PA, Muller F, Solum NO, Brosstad F, Froland SS, Aukrust AP. Enhanced activation of platelets with abnormal release of RANTES in human immunodeficiency virus type-1 infection. FASEB J 1998; 12 79-89.
7. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353: 2093-9.
8. Maher VMG, Brown BG. Lipoprotein(a) and coronary heart disease. Curr Opin Lipidol 1995; 6: 220-5.